Exhibitors Search
Liflex Science Inc
Booth no.
A60
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 19 Changni-gil, Hyeonnam-myeon, Yangyang-gun, Gangwon-do, Republic of Korea |
| Tel (Rep.) | 010-5540-9801 |
| Website |
Company Introduction
Liflex Science, Inc. is a new drug R&D company founded based on Professor Jin-Hong Kim's(Seoul National University) 20-year, KRW 10 billion-plus investment in osteoarthritis and its treatment, We aim to develop a global, first-in-class ASO injection treatment capable of fundamentally restoring osteoarthritis, a treatment previously limited to pain/inflammation treatments. We are currently in preclinical testing after confirming the substance. (1) Self-selection of the cause of osteoarthritis problem (microRNA-204) (2) Development of platform technology for decomposing the corresponding mircoRNA and development of decomposing substance/ASO and completion of patent application (3) PD/PK/Tox experiments in progress and verification completed in our own research institute (4) Currently in non-clinical stage. We are focusing on R&D by securing a total of 5 billion won in external investment/projects.
Promotional video
Exhibit Item
We aim to develop an oligonucleotide cartilage regeneration injection targeting miR-204, a key factor in the development of degenerative arthritis. Specifically, we have identified a target pathogenic factor that not only prevents disease progression but also induces cartilage regeneration. Furthermore, we have identified a substance that effectively inhibits this pathogenic factor and are conducting efficacy and toxicity testing.
Exhibit Item Images
-
Product Name : Development of an ASO Cartilage regeneration injection for Fundamental Treatment of OsteoarthritisWe aim to develop a global, first-in-class, cartilage regeneration injection that targets microRNA-204 (miR-204), a major cause of degenerative arthritis, and enables fundamental recovery of osteoarthritis sites, which was previously limited to existing pain/inflammation treatments.
Exhibit Description
Our ASO cartilage regeneration injection has now entered the GLP non-clinical phase of preparation (targeting completion and domestic IND submission by 2026). With the shortest development timeline, we aim to complete approval by 2030. By simultaneously pursuing Phase 1 and 2 clinical trials, We aim to complete Phase 3 within four years (by 2030).
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.